NGNE icon

Neurogene

22.61 USD
-0.03
0.13%
Updated Dec 23, 9:46 AM EST
1 day
-0.13%
5 days
-8.61%
1 month
1.30%
3 months
-43.64%
6 months
-28.79%
Year to date
13.79%
1 year
43.01%
5 years
49.74%
10 years
49.74%
 

About: Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Employees: 91

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

667% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 3

30% more funds holding

Funds holding: 66 [Q2] → 86 (+20) [Q3]

16% more capital invested

Capital invested by funds: $499M [Q2] → $581M (+$81.8M) [Q3]

0.9% more ownership

Funds ownership: 105.7% [Q2] → 106.6% (+0.9%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 22

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $4K

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$45
99%
upside
Avg. target
$61
169%
upside
High target
$72
218%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Mitchell Kapoor
25% 1-year accuracy
41 / 164 met price target
143%upside
$55
Buy
Reiterated
25 Nov 2024
BMO Capital
Keith Tapper
40% 1-year accuracy
2 / 5 met price target
99%upside
$45
Outperform
Maintained
20 Nov 2024
Stifel
Paul Matteis
13% 1-year accuracy
2 / 15 met price target
165%upside
$60
Buy
Maintained
12 Nov 2024
Leerink Partners
Mani Foroohar
38% 1-year accuracy
6 / 16 met price target
218%upside
$72
Outperform
Maintained
12 Nov 2024
Baird
Joel Beatty
52% 1-year accuracy
23 / 44 met price target
218%upside
$72
Outperform
Maintained
12 Nov 2024

Financial journalist opinion

Based on 16 articles about NGNE published over the past 30 days

Neutral
Accesswire
5 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
Neutral
Accesswire
6 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
Neutral
Accesswire
1 week ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
Neutral
Accesswire
1 week ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
NEW YORK, NY / ACCESWIRE / December 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
Neutral
Accesswire
1 week ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
Neutral
PRNewsWire
2 weeks ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ: NGNE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
Neutral
Accesswire
3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / November 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out
Neutral
Accesswire
3 weeks ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
Neutral
Accesswire
3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation
Neutral
Accesswire
3 weeks ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
Charts implemented using Lightweight Charts™